These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22780561)

  • 21. Immune-modulating interventions in critically ill septic patients: pharmacological options.
    Toft P; Tønnesen E
    Expert Rev Clin Pharmacol; 2011 Jul; 4(4):491-501. PubMed ID: 22114858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis.
    Norrby-Teglund A; Haque KN; Hammarström L
    J Intern Med; 2006 Dec; 260(6):509-16. PubMed ID: 17116001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting endotoxin in the treatment of sepsis.
    Rachoin JS; Schorr CA; Dellinger RP
    Subcell Biochem; 2010; 53():323-38. PubMed ID: 20593274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis.
    Laupland KB; Kirkpatrick AW; Delaney A
    Crit Care Med; 2007 Dec; 35(12):2686-92. PubMed ID: 18074465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammation and coagulation: implications for the septic patient.
    Dellinger RP
    Clin Infect Dis; 2003 May; 36(10):1259-65. PubMed ID: 12746771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of protein C concentrate in pediatric patients with sepsis.
    Silvani P; Camporesi A; Licari E; Wolfler A
    Minerva Anestesiol; 2005 Jun; 71(6):373-8. PubMed ID: 15886604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe sepsis, coagulation, and fibrinolysis: dead end or one way?
    Fourrier F
    Crit Care Med; 2012 Sep; 40(9):2704-8. PubMed ID: 22732284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis.
    Opal SM
    Int J Med Microbiol; 2007 Sep; 297(5):365-77. PubMed ID: 17452016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli.
    Giamarellos-Bourboulis EJ; Baziaka F; Antonopoulou A; Koutoukas P; Kousoulas V; Sabracos L; Panagou C; Perrea D; Giamarellou H
    Int J Antimicrob Agents; 2005 Feb; 25(2):168-72. PubMed ID: 15664488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical effects of use polymyxin B fixed on fibers in liver transplant patients with severe sepsis or septic shock.
    Ruberto F; Pugliese F; D'Alio A; Martelli S; Bruno K; Marcellino V; Perrella S; Cappannoli A; Mazzarino V; Tosi A; Novelli G; Rossi M; Ginanni Corradini S; Ferretti G; Berloco PB; Pietropaoli P
    Transplant Proc; 2007; 39(6):1953-5. PubMed ID: 17692664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemoperfusion with polymyxin B-immobilized fibers reduced the number of CD16+ CD14+ monocytes in patients with septic shock.
    Tsujimoto H; Ono S; Hiraki S; Majima T; Kawarabayashi N; Sugasawa H; Kinoshita M; Hiraide H; Mochizuki H
    J Endotoxin Res; 2004; 10(4):229-37. PubMed ID: 15373966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department.
    Nguyen HB; Corbett SW; Menes K; Cho T; Daugharthy J; Klein W; Wittlake WA
    Acad Emerg Med; 2006 Jan; 13(1):109-13. PubMed ID: 16365336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Afelimomab.
    Vincent JL
    Int J Clin Pract; 2000 Apr; 54(3):190-3. PubMed ID: 10829362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Endotoxin adsortion as adjuvant therapy in gram negative severe sepsis].
    Candel FJ; Martínez-Sagasti F; Borges M; Maseda E; Herrera-Gutiérrez M; Garnacho-Montero J; Maynar FJ; Zaragoza R; Mensa J; Azanza JR
    Rev Esp Quimioter; 2010 Sep; 23(3):115-21. PubMed ID: 20844841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Innate immunity signaling pathways: links between immunonutrition and responses to sepsis.
    Słotwiński R; Słotwińska S; Kędziora S; Bałan BJ
    Arch Immunol Ther Exp (Warsz); 2011 Apr; 59(2):139-50. PubMed ID: 21298487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New concepts in the pathogenesis, diagnosis and treatment of bacteremia and sepsis.
    Huttunen R; Aittoniemi J
    J Infect; 2011 Dec; 63(6):407-19. PubMed ID: 21840338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenic, immunologic, and clinical aspects of sepsis - update 2016.
    Uhle F; Chousterman BG; Grützmann R; Brenner T; Weber GF
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):917-27. PubMed ID: 27530423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic steroids in severe sepsis and septic shock.
    Patel GP; Balk RA
    Am J Respir Crit Care Med; 2012 Jan; 185(2):133-9. PubMed ID: 21680949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New perspectives on immunomodulatory therapy for bacteraemia and sepsis.
    Opal SM
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S70-3. PubMed ID: 21129935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antithrombin III in the treatment of sepsis-- new approaches to prescribing the old drug].
    Galstian GM; Shutova NA; Gorodetskiĭ VM
    Anesteziol Reanimatol; 2007; (6):66-71. PubMed ID: 18326265
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.